Clinical Trial Update: Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of AOC 1020 for facioscapulohumeral muscular dystrophy has completed enrollment; the update does not provide trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy
• Facioscapulohumeral Muscular Dystrophy Type

Drugs mentioned

• AOC 1020

Snippet

Sponsor: Avidity Biosciences, Inc. | Conditions: FSHD, FSHD1 | Phase 1, Phase 2 | Status: COMPLETED